• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13G filed by BillionToOne Inc.

    2/17/26 5:00:01 PM ET
    $BLLN
    Medical Specialities
    Health Care
    Get the next $BLLN alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    BillionToOne, Inc.

    (Name of Issuer)


    Class A common stock, par value $0.00001 per share

    (Title of Class of Securities)


    090168105

    (CUSIP Number)


    12/31/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    090168105


    1Names of Reporting Persons

    Oguzhan Atay
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    3,006,861.00
    6Shared Voting Power

    200,000.00
    7Sole Dispositive Power

    3,006,861.00
    8Shared Dispositive Power

    200,000.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    3,206,861.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    7.3 %
    12Type of Reporting Person (See Instructions)

    IN

    Comment for Type of Reporting Person:   Consists of (i) 2,227,542 shares of Class B common stock of the Issuer (as defined in Item 1(a) below) held of record by Oguzhan Atay (the Reporting Person), (ii) 779,319 shares of Class A common stock underlying stock options exercisable within 60 days of the date of this Statement held by the Reporting Person and (iii) 200,000 shares of Class A common stock held of record by the Reporting Person's spouse. Reporting Person disclaims beneficial ownership of securities held by spouse. Each share of Class B common stock is convertible into one share of Class A common stock at the option of the holder. Excludes 863,783 shares of Class A common stock underlying stock options not exercisable within 60 days of the date of this Statement held by the Reporting Person. Ownership percentage based on 44,222,971 shares, which is the sum of (i) 41,216,110 shares of Class A common stock of the Issuer outstanding as of December 5, 2025, as reported by the Issuer in its quarterly report on Form 10-Q filed with the Securities and Exchange Commission on December 10, 2025, (ii) 2,227,542 shares of Class B common stock (such shares treated as converted into shares of Class A common stock solely for the purposes of computing the percentage of ownership of the Reporting Person pursuant to Rule 13d-3 of the Securities Exchange Act of 1934, as amended), and (iii) 779,319 shares of Class A common stock underlying stock options exercisable within 60 days of the date of this Statement held by the Reporting Person.


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    BillionToOne, Inc.
    (b)Address of issuer's principal executive offices:

    1035 O'Brien Drive, Menlo Park, CA 94025
    Item 2. 
    (a)Name of person filing:

    Oguzhan Atay
    (b)Address or principal business office or, if none, residence:

    The address of the principal business office of the Reporting Person is 1035 O'Brien Drive, Menlo Park, CA 94025.
    (c)Citizenship:

    The Reporting Person is a citizen of the United States of America.
    (d)Title of class of securities:

    Class A common stock, par value $0.00001 per share
    (e)CUSIP No.:

    090168105
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    See Row 9 of the cover page for the Reporting Person and the corresponding comments.
    (b)Percent of class:

    See Row 11 of the cover page for the Reporting Person and the corresponding comments.
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    See Row 5 of the cover page for the Reporting Person and the corresponding comments.

     (ii) Shared power to vote or to direct the vote:

    See Row 6 of the cover page for the Reporting Person and the corresponding comments.

     (iii) Sole power to dispose or to direct the disposition of:

    See Row 7 of the cover page for the Reporting Person and the corresponding comments.

     (iv) Shared power to dispose or to direct the disposition of:

    See Row 8 of the cover page for the Reporting Person and the corresponding comments.

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Not Applicable
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    Not Applicable

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Oguzhan Atay
     
    Signature:/s/ Thomas Lynch, Attorney-in-fact
    Name/Title:Thomas Lynch, Attorney-in-fact
    Date:02/17/2026
    Get the next $BLLN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BLLN

    DatePrice TargetRatingAnalyst
    1/6/2026$120.00Buy
    Guggenheim
    12/1/2025Outperform
    William Blair
    12/1/2025$117.00Hold
    Jefferies
    12/1/2025$150.00Overweight
    Analyst
    12/1/2025$150.00Overweight
    Piper Sandler
    12/1/2025$145.00Buy
    Stifel
    12/1/2025$110.00Equal Weight
    Wells Fargo
    12/1/2025$160.00Buy
    BTIG Research
    More analyst ratings

    $BLLN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    BillionToOne to Report First Quarter 2026 Financial Results on May 6, 2026

    MENLO PARK, Calif., April 15, 2026 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ:BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today announced that the Company plans to release its financial results for the first quarter ended March 31, 2026 after the market close on Wednesday, May 6, 2026. BillionToOne will host a conference call to discuss its financial results at 1:30pm Pacific Time / 4:30pm Eastern Time the same day. Analysts planning to participate in the conference call should register here before the 1:30pm Pacific Time / 4:30pm Eastern Time start. A live and archived webcast for interested l

    4/15/26 8:05:00 AM ET
    $BLLN
    Medical Specialities
    Health Care

    BillionToOne Appoints Dr. Allen Chen as Vice President of Medical Affairs and Clinical Development, Oncology

    Renowned physician executive and clinician-scientist joins BillionToOne to advance oncology medical strategyMENLO PARK, Calif., April 2, 2026 /PRNewswire/ -- BillionToOne, Inc. (NASDAQ:BLLN), a next-generation molecular diagnostics company focused on making highly accurate testing accessible to all, today announced the appointment of Allen Chen, MD, MBA, FASTRO, FACHE, as Vice President of Medical Affairs and Clinical Development, Oncology. This new appointment reflects BillionToOne's continued commitment to building world-class oncology medical leadership as the company grows its Northstar liquid biopsy portfolio.

    4/2/26 9:00:00 AM ET
    $BLLN
    Medical Specialities
    Health Care

    BillionToOne Reports Fourth Quarter and Full Year 2025 Results and Raises 2026 Revenue Guidance

    MENLO PARK, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ:BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today reported its financial results for the fourth quarter and full year ended December 31, 2025 and raised guidance for full year 2026. Financial Highlights: Total revenue of $96.1 million in the fourth quarter of 2025, compared to $45.1 million in the fourth quarter of 2024, an increase of 113%.Prenatal clinical testing revenue was $86.1 million in the fourth quarter of 2025, an increase of 99% from the fourth quarter 2024.Oncology clinical testing revenue was $9.1 milli

    3/4/26 4:05:00 PM ET
    $BLLN
    Medical Specialities
    Health Care

    $BLLN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Humming Bird Ventures Management Nv disposed of 7,887,187 shares, acquired 7,887,187 shares and converted options into 7,707,188 shares (SEC Form 4)

    4 - BillionToOne, Inc. (0002070849) (Issuer)

    1/20/26 7:27:56 PM ET
    $BLLN
    Medical Specialities
    Health Care

    New insider Humming Bird Ventures Management Nv claimed ownership of 179,999 shares (SEC Form 3)

    3 - BillionToOne, Inc. (0002070849) (Issuer)

    1/20/26 7:25:53 PM ET
    $BLLN
    Medical Specialities
    Health Care

    Director Pagano Anthony was granted 4,896 shares (SEC Form 4)

    4 - BillionToOne, Inc. (0002070849) (Issuer)

    1/5/26 8:52:49 PM ET
    $BLLN
    Medical Specialities
    Health Care

    $BLLN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Guggenheim initiated coverage on BillionToOne with a new price target

    Guggenheim initiated coverage of BillionToOne with a rating of Buy and set a new price target of $120.00

    1/6/26 8:54:21 AM ET
    $BLLN
    Medical Specialities
    Health Care

    William Blair initiated coverage on BillionToOne

    William Blair initiated coverage of BillionToOne with a rating of Outperform

    12/1/25 8:36:56 AM ET
    $BLLN
    Medical Specialities
    Health Care

    Jefferies initiated coverage on BillionToOne with a new price target

    Jefferies initiated coverage of BillionToOne with a rating of Hold and set a new price target of $117.00

    12/1/25 8:27:06 AM ET
    $BLLN
    Medical Specialities
    Health Care

    $BLLN
    SEC Filings

    View All

    SEC Form DEFA14A filed by BillionToOne Inc.

    DEFA14A - BillionToOne, Inc. (0002070849) (Filer)

    4/21/26 4:26:02 PM ET
    $BLLN
    Medical Specialities
    Health Care

    SEC Form DEF 14A filed by BillionToOne Inc.

    DEF 14A - BillionToOne, Inc. (0002070849) (Filer)

    4/21/26 4:25:37 PM ET
    $BLLN
    Medical Specialities
    Health Care

    SEC Form 10-K filed by BillionToOne Inc.

    10-K - BillionToOne, Inc. (0002070849) (Filer)

    3/11/26 4:55:45 PM ET
    $BLLN
    Medical Specialities
    Health Care

    $BLLN
    Leadership Updates

    Live Leadership Updates

    View All

    BillionToOne Appoints Dr. Allen Chen as Vice President of Medical Affairs and Clinical Development, Oncology

    Renowned physician executive and clinician-scientist joins BillionToOne to advance oncology medical strategyMENLO PARK, Calif., April 2, 2026 /PRNewswire/ -- BillionToOne, Inc. (NASDAQ:BLLN), a next-generation molecular diagnostics company focused on making highly accurate testing accessible to all, today announced the appointment of Allen Chen, MD, MBA, FASTRO, FACHE, as Vice President of Medical Affairs and Clinical Development, Oncology. This new appointment reflects BillionToOne's continued commitment to building world-class oncology medical leadership as the company grows its Northstar liquid biopsy portfolio.

    4/2/26 9:00:00 AM ET
    $BLLN
    Medical Specialities
    Health Care

    BillionToOne Appoints Anthony Pagano to Board of Directors as Audit Committee Chair

    MENLO PARK, Calif., Dec. 9, 2025 /PRNewswire/ – BillionToOne, Inc. (NASDAQ:BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today announced the appointment of Anthony Pagano to its Board of Directors, effective January 1, 2026. Mr. Pagano will also serve as Chair of the Audit Committee. Mr. Pagano is currently Chief Financial Officer and Executive Vice President of Genmab, a leading international biotechnology company, a position he has held since March 2020. He joined Genmab in December 200

    12/9/25 4:07:00 PM ET
    $BLLN
    Medical Specialities
    Health Care

    $BLLN
    Financials

    Live finance-specific insights

    View All

    BillionToOne to Report First Quarter 2026 Financial Results on May 6, 2026

    MENLO PARK, Calif., April 15, 2026 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ:BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today announced that the Company plans to release its financial results for the first quarter ended March 31, 2026 after the market close on Wednesday, May 6, 2026. BillionToOne will host a conference call to discuss its financial results at 1:30pm Pacific Time / 4:30pm Eastern Time the same day. Analysts planning to participate in the conference call should register here before the 1:30pm Pacific Time / 4:30pm Eastern Time start. A live and archived webcast for interested l

    4/15/26 8:05:00 AM ET
    $BLLN
    Medical Specialities
    Health Care

    BillionToOne Reports Fourth Quarter and Full Year 2025 Results and Raises 2026 Revenue Guidance

    MENLO PARK, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ:BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today reported its financial results for the fourth quarter and full year ended December 31, 2025 and raised guidance for full year 2026. Financial Highlights: Total revenue of $96.1 million in the fourth quarter of 2025, compared to $45.1 million in the fourth quarter of 2024, an increase of 113%.Prenatal clinical testing revenue was $86.1 million in the fourth quarter of 2025, an increase of 99% from the fourth quarter 2024.Oncology clinical testing revenue was $9.1 milli

    3/4/26 4:05:00 PM ET
    $BLLN
    Medical Specialities
    Health Care

    BillionToOne to Report Fourth Quarter and Full Year 2025 Financial Results on March 4, 2026

    MENLO PARK, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ:BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today announced that the Company plans to release its financial results for fourth quarter and full year ended December 31, 2025 after the market close on Wednesday, March 4, 2026. BillionToOne will host a conference call to discuss its financial results at 1:30pm Pacific Time / 4:30pm Eastern Time the same day. To participate in the conference call, please register here before the 1:30pm Pacific Time / 4:30pm Eastern Time start. A live and archived webcast will be available

    2/17/26 8:05:00 AM ET
    $BLLN
    Medical Specialities
    Health Care